EFH
AKBA icon

Eaton Financial Holdings’s Akebia Therapeutics AKBA Stock Holding History

Eaton Financial Holdings’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-11,800
Closed -$16.4K – 135
2026
Q1 		$16.4K Hold
11,800
– – 0.01% 124
2025
Q4 		$19K Buy
+11,800
New +$24.7K 0.01% 134

Other funds holding AKBA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Eaton Financial Holdings's AKBA Position: Q2 2026 in Review

Eaton Financial Holdings sold out of Akebia Therapeutics (AKBA) in Q2 2026, closing a stake of 11,800 shares — an estimated $16.4K sold.

Eaton Financial Holdings first reported a position in AKBA in Q4 2025 and held it in 2 quarters. The position peaked at $19K in Q4 2025. 170 funds tracked by Wall St. Rank hold AKBA as of Q2 2026.

  • Eaton Financial Holdings reported no remaining Akebia Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Eaton Financial Holdings sold 11,800 Akebia Therapeutics shares in Q2 2026, an estimated $16.4K.
  • Eaton Financial Holdings first reported a position in Akebia Therapeutics in Q4 2025 and held it in 2 quarters.
  • Eaton Financial Holdings's Akebia Therapeutics position peaked at $19K in Q4 2025.
  • 170 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q2 2026.

Based on Eaton Financial Holdings's 13F filing for Q2 2026, filed 5 Aug 2026.